Recombinant Glucagon-like Peptide-1 (7-36 amide) Lowers Fasting Serum Glucose in a Broad Spectrum of Patients with Type 2 Diabetes

Abstract AIMS: To evaluate the safety and efficacy of various doses of recombinant glucagon-like peptide-1 (7-36) amide (rGLP-1) administered subcutaneously (s. c.) via bolus injection or continuous infusion to lower fasting serum glucose (FSG) levels in subjects with type 2 diabetes treated by diet...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hormone and metabolic research 2003-10, Vol.35 (10), p.611-616
Hauptverfasser:	Ehlers, M. R., Klaff, L. J., D’Alessio, D. A., Brazg, R., Kay, H. D., Harley, R. E., Mathisen, A. L., Schneider, R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Blood Glucose - analysis Cross-Over Studies Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Double-Blind Method Drug Therapy, Combination Fasting Glucagon - blood Glucagon-Like Peptide 1 Glucagon-Like Peptides Humans Hypoglycemic Agents - administration & dosage Insulin - administration & dosage Insulin - blood Metformin - administration & dosage Original Clinical Peptide Fragments - administration & dosage Peptide Fragments - adverse effects Placebos Recombinant Proteins - administration & dosage Sulfonylurea Compounds - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!